Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genetic markers of bevacizumab-induced hypertension.
Lambrechts D, Moisse M, Delmar P, Miles DW, Leighl N, Escudier B, Van Cutsem E, Bansal AT, Carmeliet P, Scherer SJ, de Haas S, Pallaud C. Lambrechts D, et al. Angiogenesis. 2014 Jul;17(3):685-94. doi: 10.1007/s10456-014-9424-7. Epub 2014 Feb 21. Angiogenesis. 2014. PMID: 24558090
Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
Perez EA, de Haas SL, Eiermann W, Barrios CH, Toi M, Im YH, Conte PF, Martin M, Pienkowski T, Pivot XB, Burris HA 3rd, Stanzel S, Patre M, Ellis PA. Perez EA, et al. Among authors: de haas sl. BMC Cancer. 2019 May 30;19(1):517. doi: 10.1186/s12885-019-5687-0. BMC Cancer. 2019. PMID: 31146717 Free PMC article. Clinical Trial.
Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE.
Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, Martin M, Pienkowski T, Pivot XB, Burris HA 3rd, Petersen JA, De Haas S, Hoersch S, Patre M, Ellis PA. Perez EA, et al. Cancer. 2019 Nov 15;125(22):3974-3984. doi: 10.1002/cncr.32392. Epub 2019 Jul 18. Cancer. 2019. PMID: 31318460 Free article.
Markers of response for the antiangiogenic agent bevacizumab.
Lambrechts D, Lenz HJ, de Haas S, Carmeliet P, Scherer SJ. Lambrechts D, et al. J Clin Oncol. 2013 Mar 20;31(9):1219-30. doi: 10.1200/JCO.2012.46.2762. Epub 2013 Feb 11. J Clin Oncol. 2013. PMID: 23401453 Review.
VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials.
Lambrechts D, Claes B, Delmar P, Reumers J, Mazzone M, Yesilyurt BT, Devlieger R, Verslype C, Tejpar S, Wildiers H, de Haas S, Carmeliet P, Scherer SJ, Van Cutsem E. Lambrechts D, et al. Lancet Oncol. 2012 Jul;13(7):724-33. doi: 10.1016/S1470-2045(12)70231-0. Epub 2012 May 17. Lancet Oncol. 2012. PMID: 22608783
Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
Perez EA, de Haas SL, Eiermann W, Barrios CH, Toi M, Im YH, Conte PF, Martin M, Pienkowski T, Pivot XB, Burris HA 3rd, Stanzel S, Patre M, Ellis PA. Perez EA, et al. Among authors: de haas sl. BMC Cancer. 2019 Jun 24;19(1):620. doi: 10.1186/s12885-019-5831-x. BMC Cancer. 2019. PMID: 31234810 Free PMC article.
Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.
Baselga J, Lewis Phillips GD, Verma S, Ro J, Huober J, Guardino AE, Samant MK, Olsen S, de Haas SL, Pegram MD. Baselga J, et al. Among authors: de haas sl. Clin Cancer Res. 2016 Aug 1;22(15):3755-63. doi: 10.1158/1078-0432.CCR-15-2499. Epub 2016 Feb 26. Clin Cancer Res. 2016. PMID: 26920887 Free PMC article. Clinical Trial.
35 results